Drug Trial Radar · NCT00864071
A Relative Bioavailability Study of Griseofulvin 125 mg/5 mL Suspension Under Fasting Conditions
Last checked: Nov 19, 2026Latest source record: Aug 16, 2010 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
50
Actual
Start
Nov 2005
Primary completion
Nov 2005
Study completion Nov 2005
Sponsor
- Lead sponsor
- Actavis Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 18, 2009
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
To compare the rate and extent of absorption of griseofulvin from a test formulation of Griseofulvin 125 mg/5 mL Suspension versus the reference Grifulvin V® 125 mg/5 mL Suspension under fasting conditions.
Conditions
- Healthy
Interventions
Griseofulvin 125 mg/5 mL Suspension, single doseDrug
A: Experimental Subjects received Alpharma formulated products under fasting conditions
Grifulvin V® 125 mg/5 mL Suspension, single doseDrug
B: Active comparator Subjects received Ortho Neutrogena formulated products under fasting conditions
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rate and Extend of AbsorptionTime frame: 120 hours
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Biovail Contract Research (A Division of Biovail Corporation)
Toronto, Ontario, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.